INDIGO, a consortium of public and private R&D organisations for development of improved influenza virus vaccines, has started a Phase 1 trial with a novel, adjuvanted, low-dose seasonal influenza vaccine. Safety, tolerability, and immunogenicity of TETRALITE, a combination of 1/5th of a dose of a licensed influenza vaccine and the novel LiteVax Adjuvant, will be investigated in healthy subjects.
“Next Generation Vaccines for Multi-Resistant Bacteria”.
Partners: Proxi Biotech ApS, Cellvax SAS, LiteVax B.V.
“Safety and immunogenicity of a CMS-adjuvanted, newly developed toxoid-based vaccine against C. difficile infection in non-rodent species”. Partners: Proxi Biotech ApS, Institut national de la Recherche agronomique (INRA), LiteVax B.V.
“Immunogenicity of recombinant SARS-CoV-2 Spike Protein Subunits plus a novel, potent adjuvant in Non-Rodent Species”; Possibilities of a Single-Low-Dose Vaccine against Coronavirus Infection”
Partners: ImmunoPrecise Antibodies, Institut de Recerca i Tecnologia Agroalimentàries (IRTA), LiteVax B.V.
“Effective and affordable flu vaccine for the globe”
LiteVax receives EU Horizon 2020 grant for the development of a next generation of flu vaccines for the globe.
“Treatment enabled by REcombinant Advanced immunotherapy Technologies for HER2 positive tumours”.
Partners: AdaptVac, University of Copenhagen, Expres2ion, Biomedical Primate Research Centre, LiteVax.
Development of a sublingual mucosal immunization technology platform for needle-free vaccination”.
Partners: InStar Technologies a.s., Helmholtz – Zentrum für Infektionsforschung GmbH, Timeline Bioresearch AB, Chimera Biotec GmbH, LiteVax B.V.
For the third time in 2018 LiteVax visited India and joined the Dutch Trade Mission. Prime Minister Mark Rutte and four Ministers were present to support the strategic relationships and economic cooperation. During this important event LiteVax signed 3 MoU's with Indian companies for vaccine development.
One of the predecessor of LiteVax LVX adjuvant proved to be superior to Freunds’ Complete/Incomplete Adjuvant in large animal species (PMID: 27693642)
Together with Radboud University Nijmegen Medical Centre (Nijmegen, NL), Xbrane Biosciences AB (Stockholm, SE), Drug Discovery Factory BV (Amsterdam, NL) LiteVax BV formed a consortium and received a EUROSTARS grant for the development of an intranasal, universal pneumococcal vaccine.